First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.

Kournoutas I, Marell P, Gile J, Peersen A, Shah P, VanDommelen K, Kamath SD, Gupta G, Akce M, Yang JD, Chen PJ, Naleid N, Mahipal A, Peterson N, Sahai V, Wee Ma W, Jin Z, Halfdanarson T, Fonkoua Kankeu L, Washburn LA, Conboy CB, Torbenson M, Goenka A, Thompson S, Venkatesh SK, Starlinger P, Roberts L, Gores GJ, Babiker H, Ahn D, Borad M, Bekaii-Saab T, Jatoi A, McWilliams RR, Ou FS, Tran NH

Open source

DOI: 10.1093/oncolo/oyaf286
Published: 2025 Nov 11
Container: The oncologist
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/oncolo/oyaf286,
  title = {First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.},
  author = {Kournoutas I and Marell P and Gile J and Peersen A and Shah P and VanDommelen K and Kamath SD and Gupta G and Akce M and Yang JD and Chen PJ and Naleid N and Mahipal A and Peterson N and Sahai V and Wee Ma W and Jin Z and Halfdanarson T and Fonkoua Kankeu L and Washburn LA and Conboy CB and Torbenson M and Goenka A and Thompson S and Venkatesh SK and Starlinger P and Roberts L and Gores GJ and Babiker H and Ahn D and Borad M and Bekaii-Saab T and Jatoi A and McWilliams RR and Ou FS and Tran NH},
  year = {2025},
  journal = {The oncologist},
  doi = {10.1093/oncolo/oyaf286},
  url = {https://doi.org/10.1093/oncolo/oyaf286}
}

RIS

TY  - JOUR
TI  - First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.
AU  - Kournoutas I
AU  - Marell P
AU  - Gile J
AU  - Peersen A
AU  - Shah P
AU  - VanDommelen K
AU  - Kamath SD
AU  - Gupta G
AU  - Akce M
AU  - Yang JD
AU  - Chen PJ
AU  - Naleid N
AU  - Mahipal A
AU  - Peterson N
AU  - Sahai V
AU  - Wee Ma W
AU  - Jin Z
AU  - Halfdanarson T
AU  - Fonkoua Kankeu L
AU  - Washburn LA
AU  - Conboy CB
AU  - Torbenson M
AU  - Goenka A
AU  - Thompson S
AU  - Venkatesh SK
AU  - Starlinger P
AU  - Roberts L
AU  - Gores GJ
AU  - Babiker H
AU  - Ahn D
AU  - Borad M
AU  - Bekaii-Saab T
AU  - Jatoi A
AU  - McWilliams RR
AU  - Ou FS
AU  - Tran NH
PY  - 2025
JO  - The oncologist
DO  - 10.1093/oncolo/oyaf286
UR  - https://doi.org/10.1093/oncolo/oyaf286
ER  -

APA

I, K., P, M., J, G., A, P., P, S., K, V., SD, K., G, G., M, A., JD, Y., PJ, C., N, N., A, M., N, P., V, S., W, W. M., Z, J., T, H., L, F. K., LA, W., CB, C., M, T., A, G., S, T., SK, V., P, S., L, R., GJ, G., H, B., D, A., M, B., T, B., A, J., RR, M., FS, O., & NH, T. (2025). First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective study.. The oncologist. https://doi.org/10.1093/oncolo/oyaf286

Source records

pubmed · retrieved 2026-09-26T22:01:44.938Z